09-14-2017 12:06 PM CET - Health & Medicine
Print

Download Global Cancer Nanomedicine Market Outlook 2022 Report

Press release from: Kuick Resarch

Over the past several years, many innovative and revolutionary techniques have been developed in order to treat cancer. These techniques range from basic surgical removal to X-ray irradiation to system wide flooding with anticancer agents. However, each of these approaches has its own series of undesirable side effects that are both dangerous and damaging to the overall health of the patient. On the contrary, recent breakthroughs in nanomedicine have managed to change all that. Now at last there is hope for a cure that is effective and can be made it safe.

Use of nanomedicines for cancer is one of the largest and most evolving segments containing multiple products in both market and clinical pipeline. Nanotechnology based liposome products could be observed as one of the most advance segment among oncology medicines. For instance, Doxil by Ortho pharmaceuticals was among first approved cancer nanomedicines by US FDA in 1995 for treating AIDS-related Kaposi’s sarcoma. DaunoXome by Galen Ltd is also a liposomal formulation used for the treatment of HIV relates Kaposi sarcoma and clinical trials for utilization of this medicine for leukemia is also under investigation. More products are at different stages of clinical trials which will be introduced in global market in coming years.

Nanoparticles are easily absorbed by cells due to smaller size and investigators used this property in disease diagnosis. Oncologists can get better idea of tumor shape and size along with exact location for better treatment. In market few nanoparticle based imaging agents are presents which are used for Magnetic Resonance (MR) imaging. For instance, Endorem by Guerbet, Resovist by Bayer and Feridex by Berlex Laboratories are SPIO nanoparticles commonly used for imaging. Besides oncology, they are also used in cardiovascular and cerebral disease diagnoses which also have mature market. Use of these nanoparticles in ultrasound based imaging has been proposed by investigators. This market has less competition and few products which gives significant opportunities to tap this segment. New products are expected to enter in this segment in coming years due to which its size is expected to increase several folds in future.

The future of cancer nanotechnology lies on a multifunctional nanoplatform that combines both therapeutic components and multimodality imaging. The ultimate goal is that multifunctional nanomedicine works as efficient, targeted in vivo drug delivery without systemic toxicity, and the dose delivered as well as the therapeutic efficacy can be accurately measured noninvasively with time. In the future, nanotechnology could possibly be strategically implemented in new developing drug delivery systems which could lead to significant expansion in the drug markets. These new drug delivery methods are likely to provide the appropriate platform for the pharmaceutical companies to reformulate their existing drugs in the market. This would in turn lead to extending the life of their products and ensuring an improved performance of drugs by increasing effectiveness, safety and patient adherence, and ultimately reducing healthcare costs.

“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview and Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design and Strategy
Cancer Nanomedicine as Diagnostic and Therapeutics Tool
Global Cancer Nanomedicine Market Overview and Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: www.kuickresearch.com/report-global-cancer-nanomedicine-m...

Cancer Nanomedicine: An Optimistic Avenue
1.1 Introduction
1.2 Emergence of Nanomedicines

Prerequisite of Nanomedicines
2.1 Conventional Cancer Treating Approaches
2.2 Nanomedicines: Overcoming the Hurdles

Diversification of Nanomedicines
3.1 Classification on Basis of Constituents
3.1.1 Inorganic Nanoparticles
3.1.2 Organic Nanoparticles
3.2 Classification on Basis of Applicability
3.2.1 Nanomedicine as Diagnostic Agents
3.2.2 Nanomedicine as Therapeutic Agents
3.2.3 Nanomedicine as Drug Delivery Agents
3.3 Classification on Basis of Dimensions

Mechanism of Action of Nanomedicine
4.1 Targeting Tumor Cells
4.1.1 Passive Targeting
4.1.2 Active Targeting
4.2 Nanocarrier - Drug Complex
4.2.1 Liposomes
4.2.2 Dendrimers
4.2.3 Micelles
4.2.4 Inorganic Nanocarriers
4.3 Drug Release Systems

Nanomedicine Engineering: Design and Strategy
5.1 Organic Nanoparticles as Nanomedicines
5.1.1 Polymeric Nanoparticle
5.1.2 Lipid Organic Nanoparticles
5.2 Inorganic Nanoparticles as Nanomedicines
5.2.1 Synthesis of Gold Nanoparticle

Cancer Nanomedicine as Diagnostic Tool
6.1 Detection of Cancer Biomarkers
6.1.1 Detection of Circulating Tumor Cell
6.2 Diagnostic Device and Nanoprobes
6.2.1 Biosensors
6.2.2 Microarrays
6.3 Quantum Dots for Early Cancer Detection
6.3.1 Detection of primary Cancers
6.3.2 Quantum Dots for Tumor Imaging

Cancer Therapeutics with Nanomedicines
7.1 Nanomedicine as Therapeutic Agents
7.1.1 Photodynamic Therapy
7.1.2 Photo Thermal Therapy
7.2 Nanomedicines as Prophylactic and Therapeutic Approach
7.2.1 Cancer Cell Destruction
7.3 Nanomedicine in Breast Cancer
7.4 Nanomedicine in Pancreatic Cancer
7.5 Nanomedicine in Brain Cancer
7.6 Nanomedicine in Lung Cancer

Cancer Imaging with Nanomedicine
8.1 Positron Emission Tomography
8.1.1 Applications in various Cancers
8.2 Single Photon Emitted Tomography
8.2.1 Computed Tomography
8.3 Magnetic Resonance Imaging (MRI)
8.3.1 Optical Imaging

Drug Delivery with Nanomedicines
9.1 Nanocarrier and Chemotherapy
9.1.1 Peptide Nanomedicine- An Example of Nanocarrier Chemotherapy
9.2 Nanomedicine Endocytosis and Intracellular Mechanisms
9.3 Factors Affecting Drug Delivery

Global Cancer Nanomedicine Market Overview
10.1 Current Market Scenario
10.2 Global Cancer Nanomedicine Clinical Pipeline Overview

Global Nanomedicine Market Dynamics
11.1 Encouraging Market Aspects
11.2 Commercialization Challenges

Global Cancer Nanomedicine Future Prospect

Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-III

Marketed Cancer Nanomedicine Clinical Insight by Company, Indication and Phase
14.1 Caelyx and Doxil
14.2 Albumin-Bound Paclitaxel (Abraxane and Coraxane)
14.3 Nilotinib (Tasigna)
14.4 Paclitaxel Polymeric Micelle Formulation (Cynviloq and Genexol-PM)
14.5 Paclitaxel Liposomal
14.6 Vincristine Liposomal (Marqibo)
14.7 Rexin-G
14.8 Paclitaxel Nanoparticle (Nanoxel)

Competitive Landscape
15.1 Abraxis BioScience
15.2 Access Pharmaceuticals
15.3 Alnylam Pharmaceuticals
15.4 Amgen
15.5 Arrowhead Research
15.6 BIND Therapeutics
15.7 Cadila Healthcare
15.8 Celegen Corporation
15.9 Celsion Corporation
15.10 Genzyme Corporation
15.11 Merck
15.12 NanoCarrier
15.13 Nippon Kayaku
15.14 Nanobiotix
15.15 Novavax
15.16 Pfizer
15.17 Roche
15.18 Samyang
15.19 Sanofi
15.20 Takeda Pharmaceutical

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.
News-ID: 716812 • Views: 122
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: